Journal Mobile Options
Table of Contents
Vol. 49, No. 1, 2003
Issue release date: December 2002
Eur Neurol 2003;49:20–29
(DOI:10.1159/000067018)

Crossover Comparison of Efficacy and Preference for Rizatriptan 10 mg versus Ergotamine/Caffeine in Migraine

Christie S. · Göbel H. · Mateos V. · Allen C. · Vrijens F. · Shivaprakash M.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Rizatriptan is a selective 5-HT1B/1D receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine. This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy. Of patients expressing a preference (89.1%), more than twice as many preferred rizatriptan to ergotamine/caffeine (69.9 vs. 30.1%, p ≤ 0.001). Faster relief of headache was the most important reason for preference, cited by 67.3% of patients preferring rizatriptan and 54.2% of patients who preferred ergotamine/caffeine. The co-primary endpoint of being pain free at 2 h was also in favor of rizatriptan. Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p ≤ 0.001), rizatriptan being superior within 1 h of treatment. Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p ≤ 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing. Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p ≤ 0.001). Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p ≤ 0.001). More patients were (completely, very or somewhat) satisfied 2 h after treatment with rizatriptan (69.8%) than at 2 h after treatment with ergotamine/caffeine (38.6%, p ≤ 0.001). Recurrence rates were 31.4% with rizatriptan and 15.3% with ergotamine/caffeine. Both active treatments were well tolerated. The most common adverse events (incidence ≧5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Goldstein J, Ryan R, Jiang K, Getson A, Norman B, Block GA, Lines C: Crossover comparison of rizatriptan 5 mg and 10 mg vs. sumatriptan 25 mg and 50 mg in migraine. Headache 1998;38:737–747.
  2. Teall J, Tuchman M, Cutler N, Gross M, Willoughby E, Smith B, Jiang K, Reines S, Block G: Rizatriptan (Maxalt) for the acute treatment of migraine and migraine recurrence: A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. Headache 1998;38:281–287.
  3. Anderson JR, Drehsen G, Pitman IH: Effect of caffeine on ergotamine absorption from rat small intestine. J Pharm Sci 1981;70:651–657.
  4. Schmidt R, Fanchamps A: Effect of caffeine on intestinal absorption of ergotamine in man. Eur J Clin Pharmacol 1974;7:213–216.
  5. UK Summary of Product Characteristics for Cafergot tablets. Electronic Medicines Compendium. www.emc.vhn.net/professional.
  6. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group: A randomized, double blind comparison of sumatriptan and cafergot in the acute treatment of migraine. Eur Neurol 1991;31:314–322.
  7. Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ: Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot®) in the acute treatment of migraine: A multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol 2002;47:99–107.
  8. Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 1988;8(suppl 7):1–96.
  9. Juniper EF, Guyatt GH, Jaeschke R: Analysis of binary and categorical data; in Spilker B (ed): Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia, Lippincott-Raven, 1996, pp 49–131.
  10. Jones B, Kenward G: Design and Analysis of Crossover Trials. London, Chapman & Hall, 1989.
  11. Allen C, Jiang K, Malbecq W, Goadsby PJ: Time-to-event analysis, or who gets better sooner? An emerging concept in headache study methodology. Cephalalgia 1999;19:552–556.
  12. Hartmaier SL, Santanello NC, Epstein RS, Silberstein SD: Development of a brief 24-hour migraine-specific quality of life questionnaire. Headache 1995;35:320–329.
  13. Santanello NC, Hartmaier SL, Epstein RS, Silberstein SD: Validation of a new quality of life questionnaire for acute migraine headache. Headache 1995;35:330–337.
  14. Pascual J, Bussone G, Hernandez JF, Allen C, Vrijens F, Patel K: Comparison of preference for rizatriptan 10-mg wafer versus sumatriptan 50-mg tablet in migraine. Eur Neurol 2001;45:275–283.
  15. Lipton RB, Stewart WF: Acute migraine therapy: Do doctors understand what patients want from therapy? Headache 1999;39(suppl 2): S20–S26.
  16. Tfelt-Hansen P, Block G, Dahlof C, Diener HC, Ferrari MD, Goadsby PJ, Guidetti V, Jones B, Lipton RB, Massiou H, Meinert C, Sandrini G, Steiner T, Winter PB: Guidelines of controlled trials of drugs in migraine: Second edition. Cephalalgia 2000;20:765–786.
  17. Tfelt-Hansen P, Saxena PR, Dahlof C, Pascual J, Lainez M, Henry P, Diener H, Schoenen J, Ferrari MD, Goadsby PJ: Ergotamine in the acute treatment of migraine: A review and European consensus. Brain 2000;123:9–18.

    External Resources

  18. Winner P, Ricalde O, Le Force B, Saper J, Margul B: A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996;53:180–184.
  19. Boureau F, Kappos L, Schoenen J, Esperanca P, Ashford E: A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. Int J Clin Pract 2000;54:281–286.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50